Nano-hydroxyapatite film as a support to improve the proliferation of human umbilical vein endothelial cells

doi:10.3969/j.issn.2095-4344.2015.12.010

Abstract

Abstract:

BACKGROUND: A new type of nano-hydroxyapatite artificial mechanical heart valve has been developed using pulsed laser deposition technology at the Department of Materials, Hefei University and Anhui Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, China.
OBJECTIVE: To investigate the compatibility of nano-hydroxyapatite artificial mechanical heart valve with human umbilical vein endothelial cells.
METHODS: Human umbilical vein endothelial cells were in vitro isolated, cultured and passaged to the 2-4 generations, and then the cell suspension was inoculated onto the nano-hydroxyapatite artificial mechanical heart valve. After 3, 7, 12 days of culture, the cell growth on the artificial mechanical heart valve was observed under scanning electron microscope. In addition, the human umbilical vein endothelial cells were respectively cultured in room-temperature and high-temperature extract liquids of nano-hydroxyapatite artificial mechanical heart valve, high-density polyethylene and phenol solution extracts for 72 hours, and then, the proliferation of cells was detected by MTT method.
RESULTS AND CONCLUSION: Under the scanning electron microscope, the human umbilical vein endothelial cells were fusiform- or polygon-shaped with protuberances adhered to the artificial mechanical heart value at 3 days of culture; the cells were stretched thoroughly and fused at 7 days of culture; and the cells were confluent to pieces that tightly overlaid the heart valve surface and the extracellular matrix was formed locally at 21 days of culture. Results from MTT test displayed that the nano-hydroxyapatite artificial mechanical heart valve had no cytotoxicity to the human umbilical vein endothelial cells, indicating a good cytocompatibility.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

全文链接：

Key words: Durapatite, Endothelial Cells, Umbilical Veins

CLC Number:

R318

Cheng Guang-cun, Yan Zhong-ya, Li Chun-sheng, Yan Yu, Wei Xiao-yong. Nano-hydroxyapatite film as a support to improve the proliferation of human umbilical vein endothelial cells[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(12): 1852-1857.

Figures/Tables 3

References

[1] 范瑞新,吴若彬,肖学钧,等.二尖瓣主动脉瓣三尖瓣同时置换治疗重症风湿性瓣膜病[J].中华胸心血管外科杂志, 2003,19(4): 208-210.
[2] 赵铁夫,王盛宇,周其文,等.心脏瓣膜种类选择对老年患者生活质量影响的临床对照研究[J].中国胸心血管外科临床杂志, 2013,20(4):430-434.
[3] Conrotto F, D'Ascenzo F,Salizzoni S,et al. A gender based analysis of predictors of all cause death after transcatheter aortic valve implantation.Am J Cardiol.2014;114(8): 1269-1274.
[4] Chopard R,Perrotti A,Durst C,et al. Six-year outcomes after non-resective mitral valve repair with artificial chordae using removable clips.J Heart Valve Dis.2014;23(3): 364-369.
[5] Noble S,Frangos E,Samaras N,et al.Transcatheter aortic valve implantation in nonagenarians: effective and safe. Eur J Intern Med.2013;24(8):750-755.
[6] Baraki H,Al Ahmad A,Jeng-Singh S,et al.Pacemaker dependency after isolated aortic valve replacement: do conductance disorders recover over time? Interact Cardiovasc Thorac Surg.2013;16(4):476-481.
[7] Sfeir PM,Abchee AB,Ghazzal Z,et al.Endovascular transcatheter aortic valve implantation: an evolving standard.J Cardiothorac Vasc Anesth.2013;27(4):765-778.
[8] Said SM,Burkhart HM,Dearani JA.Surgical management of congenital (non-Ebstein) tricuspid valve regurgitation. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2012;15(1): 46-60.
[9] Coats L,Tsang V,Khambadkone S,et al.The potential impact of percutaneous pulmonary valve stent implantation on right ventricular outflow tract re-intervention.Eur J Cardiothorac Surg.2005;27(4):536-543.
[10] Sun W,Martin C,Pham T.Computational modeling of cardiac valve function and intervention. Annu Rev Biomed Eng. 2014;16(1):53-76.
[11] Zahn R,Gerckens U,Linke A,et al.Predictors of one-year mortality after transcatheter aortic valve implantation for severe symptomatic aortic stenosis.Am J Cardiol.2013; 112(2):272-9.
[12] Helder MR,Schaff HV,Dearani JA,et al.Management of mitral regurgitation in Marfan syndrome: Outcomes of valve repair versus replacement and comparison with myxomatous mitral valve disease.J Thorac Cardiovasc Surg.2014;148(3): 1020-1024.
[13] Claiborne TE,Sheriff J,Kuetting M,et al.In vitro evaluation of a novel hemodynamically optimized trileaflet polymeric prosthetic heart valve.J Biomech Eng.2013;135(2):21021.
[14] Jackson MJ,Robinson GM,Ali N,et al.Surface engineering of artificial heart valve disks using nanostructured thin films deposited by chemical vapour deposition and sol-gel methods.J Med Eng Technol.2006;30(5):323-329.
[15] Ma L,Sines G.Fatigue behavior of a pyrolytic carbon. J Biomed Mater Res.2000; 51(1):61-68.
[16] Sneckenberger DS,Stinebring DR,Deutsch S,et al. Mitral heart valve cavitation in an artificial heart environment.J Heart Valve Dis.1996;5(2):216-227.
[17] Fenglan X,Yubao L,Xiaoming Y,et al.Preparation and in vivo investigation of artificial cornea made of nano-hydroxyapatite/ poly(vinyl alcohol) hydrogel composite.J Mater Sci Mater Med. 2007;18(4):635-640.
[18] Ito M,Kotani Y,Hojo Y,et al.Evaluation of hydroxyapatite ceramic vertebral spacers with different porosities and their binding capability to the vertebral body: an experimental study in sheep.J Neurosurg Spine.2007;6(5):431-437.
[19] Siriphannon P,Monvisade P,Jinawath S,et al.Preparation and characterization of hydroxyapatite/poly (ethylene glutarate) biomaterials.J Biomed Mater Res A. 2007;81(2):381-91.
[20] 王晓伟,叶福林,徐志云,等.人脐静脉血管内皮细胞构建组织工程心脏瓣膜及其生理功能[J].江苏医药,2007,33(2):156-158.
[21] 王晓伟,徐志云,张宝仁,等.人脐静脉内皮细胞用于构建组织工程心脏瓣膜的实验研究[J].第二军医大学学报,2003,24(12): 1287-120.
[22] Weymann A,Schmack B,Okada T,et al.Reendothelialization of human heart valve neoscaffolds using umbilical cord-derived endothelial cells.Circ J.2013;77(1): 207-216.
[23] Sha JM,Yan ZY,Cheng GC,et al.In-vitro seeding of human umbilical cord vein endothelial cells on hydroxyapatite for mechanical heart valve applications.J Heart Valve Dis.2010; 19(4):506-512.
[24] Martínez GJ,Seco M,Jaijee SK,et al.Introduction of an interdisciplinary heart team-based transcatheter aortic valve implantation programme: short and mid-term outcomes.Intern Med J.2014;44(9):876-883.
[25] 郝和平.医疗器械生物学评价标准实施指南[M].北京:中国标准出版社,2002: 100-10.
[26] Orme NM,Wright TC,Harmon GE,et al.Imaging Pandora's Box: incidental findings in elderly patients evaluated for transcatheter aortic valve replacement.Mayo Clin Proc.2014; 89(6):747-753.
[27] Sadat-Shojai M,Khorasani MT,Jamshidi A.3-Dimensional cell-laden nano-hydroxyapatite/protein hydrogels for bone regeneration applications.Mater Sci Eng C Mater Biol Appl. 2015;49:835-843.
[28] de Bruyn JR,Goiko M,Mozaffari M,et al.Dynamic light scattering study of inhibition of nucleation and growth of hydroxyapatite crystals by osteopontin. PLoS One.2013; 8(2):e56764.
[29] Moroi A,Ueki K,Okabe K,et al.Comparison between unsintered hydroxyapatite/poly-L-lactic acid mesh and titanium mesh in bone regeneration of rabbit mandible. Implant Dent.2013;22(3):255-262.
[30] Smolen D,Chudoba T,Malka I,et al.Highly biocompatible, nanocrystalline hydroxyapatite synthesized in a solvothermal process driven by high energy density microwave radiation.Int J Nanomedicine.2013;8:653-668.